{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:44:56Z","timestamp":1788623096803,"version":"build-2803163510"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong Province","doi-asserted-by":"publisher","award":["2025CXPT119"],"award-info":[{"award-number":["2025CXPT119"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173371"],"award-info":[{"award-number":["82173371"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372679"],"award-info":[{"award-number":["82372679"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273069"],"award-info":[{"award-number":["82273069"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472959"],"award-info":[{"award-number":["82472959"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403283"],"award-info":[{"award-number":["82403283"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273447"],"award-info":[{"award-number":["82273447"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024QH089"],"award-info":[{"award-number":["ZR2024QH089"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QH057"],"award-info":[{"award-number":["ZR2023QH057"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024MH139"],"award-info":[{"award-number":["ZR2024MH139"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022QH102"],"award-info":[{"award-number":["ZR2022QH102"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008853","name":"Jining Medical University","doi-asserted-by":"publisher","award":["JYHL2022FZD04"],"award-info":[{"award-number":["JYHL2022FZD04"]}],"id":[{"id":"10.13039\/501100008853","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105256","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:01:47Z","timestamp":1772848907000},"page":"105256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The role of OX40 in cancer immunotherapy: A comprehensive review from mechanisms to clinical applications"],"prefix":"10.1016","volume":"221","author":[{"given":"YingYing","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rou","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingli","family":"Bie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoyu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1282-4846","authenticated-orcid":false,"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105256_bib1","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1016\/j.vaccine.2004.03.041","article-title":"Anti-tumour therapeutic efficacy of OX40L in murine tumour model","volume":"22","author":"Ali","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.critrevonc.2026.105256_bib2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1128\/MCB.18.1.558","article-title":"4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB","volume":"18","author":"Arch","year":"1998","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.critrevonc.2026.105256_bib3","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.kint.2021.02.039","article-title":"Blockade of tumor necrosis factor superfamily members CD30 and OX40 abrogates disease activity in murine immune-mediated glomerulonephritis","volume":"100","author":"Artinger","year":"2021","journal-title":"Kidney Int."},{"key":"10.1016\/j.critrevonc.2026.105256_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1158\/2326-6066.CIR-20-0317","article-title":"Arginase therapy combines effectively with immune checkpoint blockade or agonist anti-OX40 immunotherapy to control tumor growth","volume":"9","author":"Badeaux","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105256_bib5","first-page":"13","article-title":"Brain tumors induce immunoregulatory dendritic cells in draining lymph nodes that can be targeted by OX40 agonist treatment","author":"Badillo-Godinez","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105256_bib6","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1002\/j.1460-2075.1994.tb06715.x","article-title":"Molecular characterization of murine and human OX40\/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34","volume":"13","author":"Baum","year":"1994","journal-title":"EMBO J."},{"key":"10.1016\/j.critrevonc.2026.105256_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.oraloncology.2015.11.009","article-title":"OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment","volume":"52","author":"Bell","year":"2016","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105256_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011638","article-title":"Dual targeting OX40 and IL-2 receptor enhances antitumor activity through tumor-infiltrating Treg depletion and CD8(+) T-cell proliferation","volume":"13","author":"Cao","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105256_bib9","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1111\/cas.15145","article-title":"Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination","volume":"112","author":"Chu","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2026.105256_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111256","article-title":"Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects","volume":"40","author":"Cortellino","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.critrevonc.2026.105256_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev-immunol-030409-101243","article-title":"Control of immunity by the TNFR-related molecule OX40 (CD134)","volume":"28","author":"Croft","year":"2010","journal-title":"Annu Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105256_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","article-title":"The significance of OX40 and OX40L to T-cell biology and immune disease","volume":"229","author":"Croft","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2026.105256_bib13","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1158\/0008-5472.CAN-12-4174","article-title":"OX40 is a potent immune-stimulating target in late-stage cancer patients","volume":"73","author":"Curti","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105256_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004235","article-title":"First-in-human phase I\/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors","volume":"10","author":"Davis","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105256_bib15","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.2147\/OTT.S214211","article-title":"OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer","volume":"12","author":"Deng","year":"2019","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.critrevonc.2026.105256_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/1078-0432.CCR-21-0845","article-title":"A Phase I, open-label, dose-escalation study of the OX40 agonist Ivuxolimab in patients with locally advanced or metastatic cancers","volume":"28","author":"Diab","year":"2022","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105256_bib17","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41467-021-21383-1","article-title":"Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells","volume":"12","author":"Duhen","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105256_bib18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00262-014-1542-y","article-title":"Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging","volume":"63","author":"Farazi","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105256_bib19","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.apsb.2019.08.010","article-title":"Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity","volume":"10","author":"Fu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.critrevonc.2026.105256_bib20","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1021\/acsbiomaterials.1c01637","article-title":"In situ reprogramming of tumors for activating the OX40\/OX40 ligand checkpoint pathway and boosting antitumor immunity","volume":"9","author":"Gao","year":"2023","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.critrevonc.2026.105256_bib21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1158\/2326-6066.CIR-19-0798","article-title":"CD137\/OX40 bispecific antibody induces potent antitumor activity that is dependent on target coengagement","volume":"8","author":"Gaspar","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105256_bib22","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1158\/1078-0432.CCR-19-3070","article-title":"Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors","volume":"26","author":"Glisson","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105256_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.108198","article-title":"Identification of cuproptosis-related lncRNAs with the significance in prognosis and immunotherapy of oral squamous cell carcinoma","volume":"171","author":"Gong","year":"2024","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.critrevonc.2026.105256_bib24","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1158\/0008-5472.CAN-07-6484","article-title":"OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor","volume":"68","author":"Gough","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105256_bib25","article-title":"PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer","volume":"9","author":"Guo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2026.105256_bib26","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1078-0432.CCR-20-1830","article-title":"OX40 agonist BMS-986178 alone or in combination with nivolumab and\/or ipilimumab in patients with advanced solid tumors","volume":"27","author":"Gutierrez","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105256_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005471","article-title":"First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors","volume":"10","author":"Hamid","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105256_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186291","article-title":"Endothelial OX40 activation facilitates tumor cell escape from T cell surveillance through S1P\/YAP-mediated angiogenesis","volume":"135","author":"He","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105256_bib29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.21037\/tlcr.2019.08.15","article-title":"OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers","volume":"8","author":"He","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105256_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011524","article-title":"INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering","volume":"13","author":"Holay","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105256_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.878639","article-title":"PRL-3 and MMP9 expression and epithelial-mesenchymal transition markers in circulating tumor cells from patients with colorectal cancer: potential value in clinical practice","volume":"12","author":"Hong","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2026.105256_bib32","first-page":"0948","article-title":"Chronic psychological stress in oncogenesis: multisystem crosstalk and multimodal interventions","volume":"8","author":"Huang","year":"2025","journal-title":"Research (Wash D C)"},{"key":"10.1016\/j.critrevonc.2026.105256_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2025.120484","article-title":"AI-powered liquid biopsy for early detection of gastrointestinal cancers","volume":"577","author":"Hussain","year":"2025","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.critrevonc.2026.105256_bib34","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3892\/ol.2022.13308","article-title":"Intratumoral expression analysis reveals that OX40 and TIM-3 are prominently expressed and have variable associations with clinical outcomes in high grade serous ovarian cancer","volume":"23","author":"James","year":"2022","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2026.105256_bib35","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.4049\/jimmunol.179.6.3515","article-title":"Dendritic cell expression of OX40 ligand acts as a costimulatory, not polarizing, signal for optimal Th2 priming and memory induction in vivo","volume":"179","author":"Jenkins","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105256_bib36","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s11684-023-0996-8","article-title":"BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models","volume":"17","author":"Jiang","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.critrevonc.2026.105256_bib37","first-page":"545","article-title":"Association of PHD3 and HIF2alpha gene expression with clinicopathological characteristics in human hepatocellular carcinoma","volume":"15","author":"Jiang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2026.105256_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/v14040751","article-title":"Elevation of the plasma levels of TNF receptor 2 in association with those of CD25, OX40, and IL-10 and HTLV-1 proviral load in acute adult T-cell leukemia","volume":"14","author":"Kato","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.critrevonc.2026.105256_bib39","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1074\/jbc.273.10.5808","article-title":"Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation","volume":"273","author":"Kawamata","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2026.105256_bib40","article-title":"Spatially tuned localization of interleukins and OX40 agonists enhances synergistic anti-tumor immunity","author":"Klich","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.critrevonc.2026.105256_bib41","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1021\/acs.molpharmaceut.1c00681","article-title":"Inactivated cowpea mosaic virus in combination with OX40 agonist primes potent antitumor immunity in a bilateral melanoma mouse model","volume":"19","author":"Koellhoffer","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105256_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40425-019-0570-8","article-title":"The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation","volume":"7","author":"Kvarnhammar","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105256_bib43","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1158\/1535-7163.MCT-24-0330","article-title":"A novel designed anti-PD-L1\/OX40 bispecific antibody augments both peripheral and tumor-associated immune responses for boosting antitumor immunity","volume":"24","author":"Li","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105256_bib44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ymeth.2021.08.001","article-title":"NetAUC: a network-based multi-biomarker identification method by AUC optimization","volume":"198","author":"Li","year":"2022","journal-title":"Methods"},{"key":"10.1016\/j.critrevonc.2026.105256_bib45","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/jso.27726","article-title":"Soluble levels of 4-1BB (CD137) and OX40 (CD134) are associated with cancer progression in gastric adenocarcinoma","volume":"130","author":"Lima","year":"2024","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105256_bib46","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70042","article-title":"Autoimmune astrocytopathy double negative for AQP4-IgG and GFAP-IgG: retrospective research of clinical practice, biomarkers, and pathology","volume":"30","author":"Lin","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.critrevonc.2026.105256_bib47","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.7150\/thno.83495","article-title":"OX40L-armed oncolytic virus boosts T-cell response and remodels tumor microenvironment for pancreatic cancer treatment","volume":"13","author":"Liu","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2026.105256_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109637","article-title":"OX40 shapes an inflamed tumor immune microenvironment and predicts response to immunochemotherapy in diffuse large B-cell lymphoma","volume":"251","author":"Lu","year":"2023","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105256_bib49","doi-asserted-by":"crossref","first-page":"15856","DOI":"10.1038\/s41598-022-19972-1","article-title":"Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia","volume":"12","author":"Marconato","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105256_bib50","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s40425-019-0827-2","article-title":"High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer","volume":"7","author":"Massarelli","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105256_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/v17111445","article-title":"Association between FOXP3 and OX40 expression in adult T-cell leukemia cells","volume":"17","author":"Mizuguchi","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.critrevonc.2026.105256_bib52","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1182\/blood.2022016052","article-title":"Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation","volume":"141","author":"Mo","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105256_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107099","article-title":"Bifunctional macromolecule activating both OX40 and interferon-alpha signaling displays potent therapeutic effects in mouse HBV and tumor models","volume":"89","author":"Mo","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105256_bib54","doi-asserted-by":"crossref","first-page":"5990","DOI":"10.4049\/jimmunol.181.9.5990","article-title":"OX40 costimulatory signals potentiate the memory commitment of effector CD8+ T cells","volume":"181","author":"Mousavi","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105256_bib55","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1158\/1078-0432.CCR-21-1412","article-title":"Whole-body PET imaging of T-cell response to glioblastoma","volume":"27","author":"Nobashi","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105256_bib56","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41416-020-0810-1","article-title":"OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody","volume":"122","author":"Ohmura","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105256_bib57","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1006\/mthe.2002.0699","article-title":"OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases","volume":"6","author":"Pan","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105256_bib58","doi-asserted-by":"crossref","first-page":"6406","DOI":"10.1158\/1078-0432.CCR-19-1259","article-title":"Anti-OX40 antibody directly enhances the function of tumor-reactive CD8(+) T cells and synergizes with PI3Kbeta inhibition in PTEN loss melanoma","volume":"25","author":"Peng","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105256_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1581398","article-title":"PSMD12 promotes hepatocellular carcinoma progression by stabilizing CDK1","volume":"16","author":"Peng","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105256_bib60","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1084\/jem.20071341","article-title":"OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection","volume":"205","author":"Piconese","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2026.105256_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.763888","article-title":"Radiation augments the local anti-tumor effect of in situ vaccine with CpG-oligodeoxynucleotides and anti-OX40 in Immunologically cold tumor models","volume":"12","author":"Pieper","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105256_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005301","article-title":"First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)","volume":"11","author":"Postel-Vinay","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105256_bib63","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1186\/s12885-018-4339-0","article-title":"High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy","volume":"18","author":"Ramser","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105256_bib64","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1615\/CritRevImmunol.v29.i3.10","article-title":"The role of OX40-mediated co-stimulation in T-cell activation and survival","volume":"29","author":"Redmond","year":"2009","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105256_bib65","first-page":"2057","article-title":"High blood levels of soluble OX40 (CD134), an immune costimulatory molecule, indicate reduced survival in patients with advanced colorectal cancer","volume":"42","author":"Sawada","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105256_bib66","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1158\/2326-6066.CIR-17-0292","article-title":"Concurrent PD-1 blockade negates the effects of OX40 agonist antibody in combination immunotherapy through inducing T-cell apoptosis","volume":"5","author":"Shrimali","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105256_bib67","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.4049\/jimmunol.179.3.1427","article-title":"Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells","volume":"179","author":"So","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105256_bib68","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1892265","article-title":"Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity","volume":"10","author":"Sturgill","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105256_bib69","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/jnu.70037","article-title":"The effectiveness of death education on death anxiety, depression, and quality of life in patients with advanced cancer: a meta-analysis of randomised controlled trials","volume":"57","author":"Su","year":"2025","journal-title":"J. Nurs. Sch."},{"key":"10.1016\/j.critrevonc.2026.105256_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113993","article-title":"Disorders of cancer metabolism: the therapeutic potential of cannabinoids","volume":"157","author":"Sun","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105256_bib71","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1186\/s12967-023-04504-w","article-title":"Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy","volume":"21","author":"Sun","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105256_bib72","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00262-021-02982-9","article-title":"Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21","volume":"71","author":"Thangaraj","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105256_bib73","article-title":"OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum","volume":"4","author":"van der Sluis","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105256_bib74","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1182\/blood-2007-01-070748","article-title":"OX40 costimulation turns off Foxp3+ Tregs'","volume":"110","author":"Vu","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105256_bib75","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/ajh.26586","article-title":"A novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia","volume":"97","author":"Wang","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105256_bib76","doi-asserted-by":"crossref","first-page":"37588","DOI":"10.18632\/oncotarget.5940","article-title":"'OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer'","volume":"6","author":"Weixler","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105256_bib77","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.prp.2010.05.016","article-title":"Costimulatory molecule OX40\/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study","volume":"206","author":"Xie","year":"2010","journal-title":"Pathol. Res Pract."},{"key":"10.1016\/j.critrevonc.2026.105256_bib78","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.ymthe.2022.06.010","article-title":"An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ","volume":"30","author":"Ye","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105256_bib79","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41423-023-01093-y","article-title":"The OX40-TRAF6 axis promotes CTLA-4 degradation to augment antitumor CD8(+) T-cell immunity","volume":"20","author":"Yu","year":"2023","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105256_bib80","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba7308","article-title":"A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105256_bib81","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2263229","article-title":"An analysis of reported cases of hemophagocytic lymphohistiocytosis (HLH) after COVID-19 vaccination","volume":"19","author":"Zhang","year":"2023","journal-title":"Hum. Vaccin Immunother."},{"key":"10.1016\/j.critrevonc.2026.105256_bib82","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2024.2426305","article-title":"SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity","volume":"25","author":"Zhang","year":"2024","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105256_bib83","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1038\/s41467-022-35130-7","article-title":"Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy","volume":"13","author":"Zhu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105256_bib84","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.4049\/jimmunol.173.6.3716","article-title":"Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions","volume":"173","author":"Zingoni","year":"2004","journal-title":"J. Immunol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:42:21Z","timestamp":1776127341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":84,"alternative-id":["S1040842826001435"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105256","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of OX40 in cancer immunotherapy: A comprehensive review from mechanisms to clinical applications","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105256"}}